CardiovascularResearch Phase

C-type Natriuretic Peptide (CNP)

Endogenous

Overview

C-type natriuretic peptide is a 22-amino acid member of the natriuretic peptide family that selectively activates natriuretic peptide receptor B (NPR-B). Unlike ANP and BNP, CNP is produced primarily in vascular endothelium and functions as a paracrine regulator of vascular tone and endothelial permeability with minimal direct renal effects.

Mechanism of Action

CNP also plays important roles in bone growth and chondrocyte proliferation through cyclic GMP signaling..

Research Summary & Key Findings

Vosoritide, an analogue of CNP, received FDA approval in 2021 for achondroplasia based on the phase 3 trial showing increased growth velocity in pediatric patients (NEJM, 2020). Cardiovascular applications of CNP remain investigational, with preclinical studies demonstrating anti-fibrotic and anti-remodeling properties in models of vascular and cardiac disease.

Clinical Status

Research Phase

C-type Natriuretic Peptide (CNP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers C-type Natriuretic Peptide (CNP) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply C-type Natriuretic Peptide (CNP).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.